 Vaccine candidates triggered high production of neutralizing antibodies against SARS-CoV-2 and SARS-CoV-1 in preclinical studies Epitopes used in the vaccine candidates are located in regions that are not known to be susceptible to mutations, including the SARS-CoV-2 Delta Variant The vaccine candidates are stable at room temperature and can be administered using the Companys MVP technology eliminating the need for multiple doses NOVATO, CA ACCESSWIRE September 23, 2021 Mosaic ImmunoEngineering Inc. Mosaic or the Company, OTCQB:CPMV, a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, today announced the recent publication of preclinical data demonstrating that candidates from the companys Modular Vaccine Platform MVP are effective in the neutralization of SARS-CoV-2, the virus that causes COVID-19, in human cells. These and other candidates included in Mosaics MVP technology were recently licensed from the University of California, San Diego. 